Recurrent or Metastatic Head and Neck CancerPhase 1NCT07501650
Ultrasound Microbubble Cavitation + Pembrolizumab
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
What the film says
This trial is for head and neck squamous cell cancer that has come back or spread, in adults whose tumor can be treated with salvage surgery.
The idea: a vaccine made from the patient's own tumor. Tissue from surgery is used to make tumor membrane vesicles, given alone or together with pembrolizumab. Patients may have had up to three earlier regimens.
This phase 1 study looks for the safety and best dose of the vaccine, and plans 40 patients. At Emory University in Atlanta, Dong Shin leads it.
Public record; not medical advice.
Sources behind this film
Recurrent or metastatic head and neck squamous cell cancer, adults, amenable to salvage surgery; Vaccine made from the patient's own tumor tissue (tumor membrane vesicles), alone or with pembrolizumab; Phase 1; safety and best dose; 40 patients; Emory University, Atlanta; Dong Shin (+1 more lines)
The drug
PRIMARY OBJECTIVE: I. To determine the safety, tolerability, and recommended dose and schedule of TMV vaccine alone or TMV vaccine plus pembrolizumab in patients with surgically resected, recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). SECONDARY OBJECTIVE: I.
To assess vaccine-induce immune activity, antitumor response, progression-free survival (PFS) and overall survival (OS) in adult patients with recurrent and/or metastatic HNSCC administered TMV vaccine alone and TMV vaccine plus pembrolizumab. TERTIARY/EXPLORATORY OBJECTIVES: I. Determine whether TMV vaccine induces immune response and the magnitude of the response. II.
Giving TMV vaccine therapy alone or with pembrolizumab may be safe, tolerable and/or effective in treating patients with recurrent and/or metastatic head and neck squamous cell cancer.
The study
This phase Ib trial tests the safety, side effects and best dose of tumor membrane vesicle (TMV) vaccine therapy alone and in combination with pembrolizumab and evaluates how well it works in treating patients with head and neck squamous cell cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic).
Vaccines made from a person's tumor cells, such as TMV vaccines, may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.